Idebenone: A Comprehensive Reference
1. Identity and Chemical Nature
Chemical Name, Structure, and Classification
The chemical name for idebenone is 6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone. Idebenone, also known under the brand names Catena, Sovrima, and Puldysa, is a synthetic short-chain benzoquinone that functions as an electron transporter in the mitochondrial electron transport chain (ETC), assisting in the synthesis of ATP. The compound is also sold under the brand name Raxone.
Idebenone was first synthesized in Japan in the 1980s and is an analogue of coenzyme Q10 (CoQ10), the lipophilic electron carrier and endogenous antioxidant found in all cellular mitochondrial membranes. Structurally, coenzyme Q10 and idebenone share the same substituted 1,4-benzoquinone ring, but have a different side chain. The hydroxydecyl side chain makes idebenone less lipophilic than CoQ10.
The physicochemical properties of idebenone mainly differ from those of CoQ10 due to substantial differences between their tails. The natural quinone (CoQ10) presents a tail with 10 isoprenyl units, accounting for a total of 50 carbon atoms, with a strong hydrophobic character. Contrastingly, idebenone's tail is only 10 carbon atoms long and bears a terminal hydroxyl group that enables its polarity.
Natural vs. Synthetic Origin
Despite its similarity to CoQ10, idebenone cannot be isolated from any natural sources but instead was synthesized and selected as a pharmacologically active compound in the 1980s by Takeda Pharmaceuticals purely based on its pharmacological properties. This is a critical distinction: idebenone is not a natural product or botanical ingredient despite being frequently described alongside, or compared to, the naturally occurring CoQ10. Idebenone is a novel chemical entity, which was selected from a medicinal chemistry programme conducted in the 1980s by Takeda Pharmaceuticals as a pharmacologically active compound purely based on its pharmacological properties.
Common Forms and Preparations
Idebenone is commercially available in several forms:
- Oral tablets (pharmaceutical grade): Preferred formulations contain 45 mg or 150 mg of idebenone in film-coated tablets containing lactose, cellulose, croscarmellose sodium, PVP, and magnesium stearate.
- Topical cosmetic preparations: Idebenone is available topically as a cosmetic (Prevage®) and has been marketed by Allergan and Elizabeth Arden. It is incorporated into lotions at concentrations of 0.5%–1.0% for skin applications.
- Suspension formulations: Idebenone is well absorbed from the gut but undergoes excessive first-pass metabolism in the liver, so that less than 1% reaches the circulation. This rate can be improved with special formulations (suspensions) of idebenone and by administering it together with fatty food; but even taking these measures, bioavailability still seems to be considerably less than 14% in humans.
2. Historical Development and Early Use
Idebenone has no traditional or herbal history of use. Unlike many compounds discussed in the context of dietary supplements, it was not used by any culture or tradition prior to its synthesis — it did not exist until its deliberate laboratory creation. Its history is therefore entirely pharmaceutical and clinical.
Idebenone is a well-known compound, developed in the early 1980s by Takeda Pharmaceuticals against cognitive decline/dementia. In the 1970s and 1980s, far less was known about the molecular events associated with cognitive decline and dementia. At the time, one prominent theory to explain the pathology of dementia was an age-dependent irreversible change of vascular structure and function. It was in this intellectual climate that Takeda pursued idebenone as a candidate drug to address cerebrovascular and neurodegenerative conditions.
Idebenone became available in Japan as "Avan" since November 1986 for the improvement of cerebral metabolism and psychiatric symptoms in Alzheimer's disease. Idebenone was marketed in Japan from 1986 to 1998 for the treatment of cognitive difficulties following stroke. During this period, idebenone was one of the most frequently prescribed drugs following stroke, with an estimated eight million patients treated. Idebenone was removed from the market in Japan after a post-marketing study failed to demonstrate efficacy, but remains registered for cognitive disorders in Italy, Portugal, Argentina, and Ecuador.
The Swiss company Santhera Pharmaceuticals subsequently began to investigate idebenone for the treatment of neuromuscular diseases. In 2010, early clinical trials for the treatment of Friedreich's ataxia and Duchenne muscular dystrophy were completed.
3. Key Constituents and Active Compounds
Idebenone is a single, chemically defined molecule rather than a multicomponent botanical extract. Its pharmacological activity is attributed to its quinone moiety and the interplay between its oxidized (idebenone) and reduced (idebenol) forms.
The Quinone Moiety and Structural Basis of Activity
Idebenone shares its quinone moiety with CoQ10, but at the same time differs from CoQ10 by the presence of a much shorter, less lipophilic tail. Idebenone is a synthetic analog of coenzyme Q10 with strong antioxidant activities, which in addition improves mitochondrial respiratory chain function and cellular energy production.
Mechanisms of Action
Idebenone exerts its biological effects through several interlocking mechanisms. The most critical of these involve its bioactivation by the enzyme NQO1 and its subsequent interaction with the mitochondrial electron transport chain.
Bioactivation via NQO1: In the case of idebenone, bioactivation is done by NAD(P)H quinone oxidoreductase 1 (NQO1), which generates the stable hydroquinone form — the active form of the molecule. This activated idebenone molecule can donate electrons to detoxify radicals as well as to the mitochondrial respiratory chain to aid ATP production.
Complex I bypass and Complex III electron donation: Due to its shorter and less lipophilic tail, idebenone shows better penetration across mitochondrial membranes and the blood-brain barrier. It has been demonstrated that, upon reduction by the cytosolic NAD(P)H oxidoreductase I (NQO1), idebenone can be oxidized by complex III (CIII), promoting downstream mitochondrial respiration and ATP synthesis. The two-electron reduction of idebenone to idebenol is catalyzed by NQO1 and occurs primarily in the cytoplasm. Idebenol is hydrophilic enough to traverse the cytoplasm but lipophilic enough to mediate electron transfer to complex III in the mitochondrial inner membrane.
ATP restoration under complex I deficiency: The NQO1-reduced idebenone is able to donate electrons into the mitochondrial respiratory chain and can partially restore cellular ATP levels under conditions of impaired complex I function.
Antioxidant activity and lipid peroxidation inhibition: Due to its ability to inhibit lipid peroxidation, idebenone protects cell membranes and mitochondria from oxidative damage. Most prominently associated with idebenone is its potent antioxidant capacity as substantiated by the ability to prevent lipid peroxidation and reactive oxygen species (ROS) in multiple systems.
Pro-oxidant risk at complex I: It is important to note that idebenone's activity is context-dependent and not unambiguously protective. Although championed as an antioxidant, idebenone can also act as a pro-oxidant by forming an unstable semiquinone at complex I. The antioxidant function of idebenone is critically dependent on two-electron reduction to idebenol without the creation of unstable intermediates. These characteristics are supported by several reports that described idebenone toxicity and/or a lack of efficacy in test systems with low or absent NQO1 status.
NQO1 expression and the Nrf2 pathway: As NQO1 is an inducible enzyme regulated by oxidative stress and the nuclear factor erythroid 2-related factor 2 (Nrf2)/antioxidant response element (ARE) pathway, optimizing NQO1 expression in appropriate cell types within a specific disease context may be key to delivering on idebenone's therapeutic potential. However, NQO1 is not universally expressed by cells of the brain, which has been proposed as a reason for inconsistent efficacy across neurological conditions.
Additional emerging mechanisms: Emerging evidence suggests that idebenone may also have beneficial effects beyond neurological conditions through disrupting mitochondrial membrane potential, inducing mitochondrial apoptosis, promoting mitophagy, attenuating ferroptosis, and reducing reactive oxygen species and lipid peroxidation.
4. Pharmacokinetics
Idebenone is well absorbed from the gut but undergoes excessive first-pass metabolism in the liver, so that less than 1% reaches the circulation. This rate can be improved with special formulations (suspensions) of idebenone and by administering it together with fatty food, but even taking these measures bioavailability still seems to be considerably less than 14% in humans. More than 99% of the circulating drug is bound to plasma proteins.
Idebenone exhibited dose-dependent pharmacokinetics in daily doses up to 2,250 mg, and over 99% of parent idebenone was metabolized, indicating a high first-pass effect.
5. Scientific Evidence by Area of Use
5.1 Leber's Hereditary Optic Neuropathy (LHON)
This is the indication with the strongest and best-supported clinical evidence for idebenone, resulting in regulatory approval in Europe.
Leber's hereditary optic neuropathy (LHON) is one of the most frequent mitochondrial disorders. It is caused by mutations in genes of the mitochondrial DNA coding for subunits of the respiratory chain and leads to severe bilateral vision loss, from which spontaneous recovery is infrequent. Retinal ganglion cells show a selective vulnerability to mitochondrial dysfunction in LHON.
Idebenone (Raxone®) is the only disease-specific drug approved to treat visual impairment in adolescents and adults with LHON, a rare genetic mitochondrial disease that causes rapid and progressive bilateral vision loss. The mechanism of action involves its antioxidant properties and ability to act as a mitochondrial electron carrier, overcoming mitochondrial complex I respiratory chain deficiency by transferring electrons directly to mitochondrial complex III, thereby restoring cellular energy (ATP) production and re-activating retinal ganglion cells.
RHODOS Trial (Phase 3 RCT): In the Rescue of Hereditary Optic Disease Outpatient Study (RHODOS) randomized placebo-controlled clinical trial, 85 patients with LHON were enrolled within the first 5 years after symptom onset and randomized to either idebenone 900 mg/day for 6 months or placebo. A trend toward improved visual acuity was observed in idebenone-treated patients. In hindsight, the 6-month treatment duration was likely too short to fully capture the potential treatment benefit.
LEROS Study (Phase 4, Open-Label, Natural History-Controlled): Idebenone has been shown to be effective in stabilizing and restoring vision in patients treated within 1 year of onset of vision loss. The open-label, international, multicenter, natural history-controlled LEROS study assessed the efficacy and safety of idebenone treatment (900 mg/day) in patients with LHON up to 5 years after symptom onset (N = 199) and over a treatment period of 24 months, compared to an external natural history control cohort (N = 372). LEROS met its primary endpoint and confirmed the long-term efficacy of idebenone in the subacute/dynamic and chronic phases; the treatment effect varies depending on disease phase and the causative mtDNA mutation.
Findings showed 42.3% of eyes in the idebenone arm achieved clinically relevant benefit compared with 20.7% in the natural history control arm (odds ratio [OR], 2.29; P = .002).
Regulatory Status: In 2015, the European Medicines Agency (EMA) approved idebenone (Raxone®, Santhera Pharmaceuticals) for treating patients with LHON at 900 mg/day in three doses. The Food and Drug Administration (FDA) has also accepted for review a New Drug Application (NDA) for idebenone for the treatment of LHON.
Evidence strength: Moderate-to-strong for LHON. The EMA approval is based on a combination of an RCT (RHODOS), a non-randomized controlled study (LEROS), and real-world expanded access data. The approval was based on the overall data from a randomized clinical trial, a follow-up study, and real-world data. Long-term efficacy studies for idebenone in LHON are limited by the lack of direct control data, which are difficult to prospectively compile for rare diseases with an approved treatment. The EMA acknowledged that a placebo-controlled study in newly diagnosed patients is not feasible considering the rarity of LHON and the fact that idebenone is already available on the market.
5.2 Friedreich's Ataxia (FRDA)
Friedreich's ataxia is an autosomal recessive neurodegenerative disease where impaired mitochondrial function and excessive production of free radicals play a central pathogenetic role. Idebenone, a synthetic analogue of coenzyme Q, is a powerful antioxidant that was first administered to Friedreich's ataxia patients less than 10 years ago (as of 2008).
Early open-label cardiac evidence: Idebenone (5 mg/kg/day) was given orally to 38 patients with Friedreich's ataxia aged 4–22 years. Cardiac ultrasound indices were recorded before and after idebenone treatment. After six months, cardiac ultrasound indicated a reduction in left ventricular mass of more than 20% in about half the patients (p < 0.001).
Di Prospero et al. (2007, Lancet Neurology) — RCT for neurological function: 48 genetically confirmed FA patients, aged 9–17 years, were enrolled in a 6-month, randomised, double-blind, placebo-controlled study. The patients received placebo or one of three doses of idebenone (approximately 5 mg/kg, 15 mg/kg, and 45 mg/kg), stratified by body weight. Whereas an overall analysis did not show a significant difference in ICARS, FARS, or ADL total scores, there were indications of a dose-dependent response in the ICARS score.
IONIA Phase III Trial — Cardiac endpoint: In this 6-month randomized, double-blind, controlled study, 70 pediatric subjects were treated either with idebenone (450/900 mg/d or 1,350/2,250 mg/d) or with placebo to determine whether idebenone improves cardiac measures in FRDA. Idebenone did not decrease left ventricular hypertrophy or improve cardiac function in subjects with FRDA. The study does not provide evidence of benefit in this cohort over a 6-month treatment period.
Aggregate review: Results from 11 clinical studies (randomised, controlled, and open-label trials), involving a total of about 200 patients, provide evidence of improvement in both cardiac hypertrophy and neurological symptoms among patients with FRDA treated with idebenone. However, most trials demonstrated a positive effect on cardiac hypertrophy, while neurological function is in general not modified in adult patients, though a dose-dependent effect was demonstrated in young Friedreich's ataxia patients.
Regulatory outcome: In February 2013, Health Canada announced that idebenone would be voluntarily recalled as of April 2013 by its manufacturer, Santhera Pharmaceuticals, due to the failure of the drug to show efficacy in further clinical trials. In 2008, the European Medicines Agency (EMA) refused a marketing authorization for this indication. As of 2013, the drug was not approved for FA in Europe nor in the US.
Evidence strength: Mixed and insufficient for regulatory approval. Early open-label trials suggested cardiac benefit, but later, larger, and more rigorously controlled studies failed to confirm consistent effects on either cardiac or neurological outcomes. Further high-dose, long-duration trials have been recommended.
5.3 Duchenne Muscular Dystrophy (DMD)
Respiratory function decline, a predominant cause of early mortality in DMD, results from the underlying weakness and degeneration of respiratory muscle groups, notably the diaphragm, the intercostal, and chest wall muscles, leading to impaired respiratory muscle strength.
DELPHI Trial (Phase 2): A proof-of-concept, randomized, placebo-controlled phase 2 trial of 12 months duration in 21 DMD patients (DELPHI trial) provided initial evidence that idebenone has the potential to slow loss of respiratory function. Idebenone treatment resulted in a trend (p = 0.067) toward increased peak systolic radial strain in the left ventricular inferolateral wall. A significant respiratory treatment effect on peak expiratory flow was observed (p = 0.039 for PEF).
DELOS Trial (Phase 3 RCT, Lancet 2015): A confirmatory phase 3, randomized, placebo-controlled trial (DELOS trial) specifically investigated the efficacy of idebenone on respiratory function outcomes in 64 DMD patients (age 10–18 years, 92% non-ambulatory at baseline) who discontinued glucocorticoid use at least one year prior to study start. Eligible patients had abnormal respiratory function, defined as PEF%p at baseline of less than 80%.
Patients were randomised 1:1 to receive idebenone (Raxone®/Catena®) 900 mg/day or placebo for 52 weeks. The primary endpoint was change in peak expiratory flow (PEF) percent predicted from baseline to week 52. Idebenone significantly attenuated the fall in PEF%p from baseline to week 52 and also had a significant effect on PEF (L/min), weekly home-based PEF, FVC, and FEV1. Treatment with idebenone was safe and well tolerated with adverse event rates similar in both groups.
Evidence strength: Moderate — one positive Phase 3 RCT (DELOS) in a specific subset of DMD patients (non-glucocorticoid users). Idebenone had a positive impact on a measurement of respiratory function in non-ambulatory Duchenne muscular dystrophy patients who were not taking steroids. The extent to which these benefits apply to glucocorticoid-treated patients remains under investigation.
5.4 Alzheimer's Disease and Cognitive Decline
Alzheimer's disease was idebenone's original therapeutic target, motivating its synthesis and initial commercialization in Japan.
Weyer et al. (1996, Human Psychopharmacology) — 12-Month RCT: The efficacy and safety of idebenone were studied in a prospective, randomized, double-blind, placebo-controlled multicentre study in three parallel groups of patients with dementia of the Alzheimer type. A total of 450 patients were randomized to either placebo (n = 153) or idebenone 90 mg three times daily (n = 148) or 120 mg three times daily (n = 149) and treated up to 12 months. After months 6 and 12, idebenone showed statistically significant dose-dependent improvement in the primary efficacy variable ADAS-Total and in all secondary efficacy variables. An analysis of therapy responders revealed significant dose-related superiority of idebenone with respect to placebo.
Gutzmann and Hadler (1998, 2-Year Extension): The 2-year efficacy and safety of idebenone were studied in a prospective, randomized, double-blind multicentre study in three parallel groups. A total of 450 patients were randomized to either placebo for 12 months followed by idebenone 90 mg three times daily for another 12 months (n = 153), or idebenone 90 mg three times daily for 24 months (n = 148), or 120 mg three times daily for 24 months (n = 149).
Conflicting findings from a later large study: Despite positive signals in some earlier trials, a later study produced a directly contradictory conclusion. Experience from phase II and III clinical trials for Alzheimer's disease, in which patients received 120 mg, 240 mg, or 360 mg three times daily for periods of up to 2 years, suggests a relatively benign toxicity profile, but no therapeutic benefit was found.
Evidence strength: Weak and contradictory overall. Early RCTs showed dose-dependent benefits on cognitive scales, but subsequent larger or differently designed trials did not replicate these findings. Idebenone is no longer considered an established treatment for Alzheimer's disease, and its earlier Japanese marketing authorization for this indication was ultimately withdrawn.
5.5 Multiple Sclerosis
A clinical trial assessed the safety, therapeutic efficacy, and mechanism of action of idebenone in primary-progressive multiple sclerosis (PP-MS). The hypothesis was that idebenone, through its combined effect on facilitation of mitochondrial metabolism and limitation of oxygen radical-induced CNS damage, would inhibit CNS tissue destruction in PP-MS patients.
A Phase I/II trial for primary progressive multiple sclerosis concluded that idebenone did not inhibit disability progression. The IPPoMS trial studied idebenone at 2,250 mg/day in PP-MS patients.
Evidence strength: Negative. The available evidence does not support idebenone for multiple sclerosis.
5.6 Huntington's Disease
In a double-blind, placebo-controlled trial of idebenone for the treatment of Huntington's disease, 100 patients were randomized to receive idebenone 90 mg three times daily or placebo for a period of 12 months. Ninety-one patients completed the study, and no patients left the trial for adverse events attributed to idebenone. Idebenone was found to be safe and well tolerated in this study, but no benefit was found.
Evidence strength: A single completed RCT found no clinical benefit. Evidence is negative.
5.7 Emerging and Investigational Areas
As of 2022, a Phase III clinical trial was ongoing for the treatment of Parkinson's disease. A Phase I and II clinical trial for the treatment of MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) was also conducted.
Numerous clinical trials have demonstrated the effectiveness of idebenone in the treatment of neurological diseases. Emerging evidence suggests that idebenone may also have beneficial effects beyond neurological conditions through disrupting mitochondrial membrane potential, inducing mitochondrial apoptosis, promoting mitophagy, attenuating ferroptosis, and reducing reactive oxygen species and lipid peroxidation. These mechanisms are under active preclinical and early-phase clinical investigation for conditions including cancer, systemic lupus erythematosus, and vascular disease.
A 2025 observational study in Frontiers in Neurology examined cognitive function in patients with post-stroke cognitive impairment: patients from a Chinese hospital between January 2020 and December 2024 received idebenone 30 mg three times daily for 3 months, with cognitive function assessed using MoCA and MMSE at baseline and months 1, 2, and 3. This represents the continued investigation of idebenone in East Asian clinical practice for post-stroke cognitive support, though the evidence base for this indication remains limited and preliminary.
5.8 Topical Skin Applications (Photoaging)
Because of its lower molecular weight, idebenone can penetrate the skin more efficiently than coenzyme Q10. Idebenone is an effective antioxidant that suppresses melanin biosynthesis and glycation, and can protect the skin from UV-induced damage, accounting for its use in commercial anti-aging formulations.
McDaniel et al. (2005, Journal of Cosmetic Dermatology): In this non-vehicle-controlled study, 0.5% and 1.0% idebenone commercial formulations were evaluated in a clinical trial for topical safety and efficacy in photodamaged skin. Forty-one female subjects, aged 30–65, with moderate photodamaged skin were randomized to use a blind-labelled skincare preparation twice daily for six weeks. After six weeks' use of the 1.0% idebenone formula, a 26% reduction in skin roughness/dryness was observed, a 37% increase in skin hydration, a 29% reduction in fine lines/wrinkles, and a 33% improvement in overall global assessment of photodamaged skin. For the 0.5% idebenone formulation, a 23% reduction in skin roughness/dryness was observed, a 37% increase in skin hydration, a 27% reduction in fine lines/wrinkles, and a 30% improvement in overall global assessment.
Evidence strength and limitations: This study was not vehicle-controlled. Furthermore, a study in pigs revealed that idebenone offers little to no photoprotective effects when applied daily for four days before irradiation with solar-simulated UV radiation. Idebenone is claimed to have properties similar to CoQ10 in its antioxidant properties and has been used in anti-aging on the basis of free-radical theory. Clinical evidence for this use is currently limited. Overall, the dermatological evidence is preliminary and suffers from methodological limitations (small sample sizes, lack of vehicle controls, and insufficient long-term follow-up).
6. Body Systems and Health Areas
Based on completed and ongoing clinical research, idebenone has been investigated across several body systems:
- Visual/Ophthalmic System: Approved treatment for LHON; preserves retinal ganglion cell function in mitochondrial complex I deficiency disorders.
- Neuromuscular System: Investigated and partially evidenced in Duchenne muscular dystrophy (respiratory muscle function); negative or inconclusive in Friedreich's ataxia neurological endpoints.
- Cardiovascular System: Improvement in patients with cardiomyopathy treated with idebenone has been reported. There may also be some improvement in the cardiomyopathy seen in patients with Friedreich's ataxia. However, the controlled Phase 3 IONIA trial failed to replicate cardiac benefits.
- Central Nervous System: Extensively studied in Alzheimer's disease, Huntington's disease, and PPMS; the evidence base is predominantly negative or mixed for these applications.
- Respiratory System: Demonstrated benefit in slowing respiratory function decline in DMD patients in the Phase 3 DELOS trial.
- Integumentary System (Skin): Used topically in cosmetic formulations for photoaged skin; clinical evidence is limited and not vehicle-controlled.
- Immune/Inflammatory System: Preclinical (murine) data suggest potential in autoimmune disease (e.g., SLE), but human data are absent. In MRL/lpr lupus-prone mice, idebenone-treated animals showed significant attenuation in mortality and in several disease features including glomerular inflammation and fibrosis, and in renal function.
7. Dosage Forms and Dosages Used in Studies
The following dosages are reported exclusively as used in cited clinical research; they are not prescriptive recommendations.
- LHON (RHODOS Trial and LEROS Study): Enrolled patients received 900 mg/day idebenone (2 × 150 mg orally three times per day) for up to 24 months.
- Alzheimer's Disease trials: Phase II and III clinical trials used 120 mg, 240 mg, or 360 mg three times per day for periods of up to 2 years.
- Friedreich's Ataxia (open-label cardiac trials): Idebenone at 5 mg/kg/day was given orally to 38 patients aged 4–22 years.
- Friedreich's Ataxia (Di Prospero RCT, high-dose): The patients received placebo or one of three doses of idebenone (approximately 5 mg/kg, 15 mg/kg, and 45 mg/kg), stratified by body weight.
- IONIA Phase 3 (FRDA cardiac): Seventy pediatric subjects were treated either with idebenone (450/900 mg/day or 1,350/2,250 mg/day) or with placebo.
- DMD (DELOS Phase 3 Trial): Patients were randomised 1:1 to receive idebenone 900 mg/day or placebo for 52 weeks.
- Huntington's Disease RCT: 100 patients were randomized to receive idebenone 90 mg three times per day or placebo for 12 months.
- Primary Progressive MS (IPPoMS): The IPPoMS trial randomized patients to idebenone 2,250 mg/day or placebo.
- Topical (dermatology): 0.5% and 1.0% idebenone formulations applied twice daily for six weeks.
- Phase I safety (healthy volunteers): In healthy volunteers, idebenone is well tolerated when given as single oral doses up to 1,050 mg, or as multiple oral doses of 2,250 mg/day (750 mg three times daily) for 14 days.
- Dose-range used across neuromuscular trials: Patients (8 years or older) received doses of idebenone ranging from 180 or 360 mg/day to 1,350 or 2,250 mg/day, depending on body weight, or placebo.
8. Safety Considerations and Adverse Effects
General Safety Profile
There is considerable clinical trial and post-marketing experience indicating that idebenone is well tolerated and has a good safety profile. Safety data are available from 311 patients with Friedreich's Ataxia (FRDA) or Leber Hereditary Optic Neuropathy (LHON) treated with idebenone at doses of between 900 and 2,250 mg/day. No noteworthy imbalances in the distribution of adverse events were observed for the comparison of idebenone and placebo.
In clinical studies, idebenone has been well tolerated by patients with various pathological conditions. The most common adverse events have been gastrointestinal effects of mild to moderate severity. No neurotoxic or adverse cardiac reactions have been reported in pre-clinical or clinical studies.
Specific Reported Adverse Events
The most commonly observed adverse reactions were gastrointestinal disorders. The following reactions were observed in more than one patient: headache, diarrhea, nausea, and dyspepsia. The following reactions were not observed in more than one patient at the recommended doses: white blood cell count decrease, disturbance in attention, angina pectoris, vomiting, reflux oesophagitis, musculoskeletal chest pain, myalgia, and upper abdominal pain.
In Alzheimer's disease trials, patients showed the following reactions uncommonly (between 1/1,000 and 1/100): sleep disorders, nervousness, dizziness, changes in hepatic laboratory values, and influenza-like symptoms. These reactions may be more likely in this elderly study population with CNS impairment and more concomitant medications.
Neutropenia (Isolated Case)
One child receiving high-dose idebenone developed neutropenia after 6 months, which resolved after discontinuation of treatment. This represents an isolated case identified in the controlled trial literature; systematic surveillance of hematological parameters is prudent in long-term high-dose use.
Pro-oxidant Risk in Certain Contexts
Research demonstrated an accumulative deleterious effect of idebenone due to oxidative stress in healthy wild-type mice, resulting in an increase of NQO1 enzyme in response to this oxidative environment. This negative effect could be due to the impairment of complex I, or due to superoxide generation caused by the interaction between idebenone and the hydrophilic binding site within complex I. This pro-oxidant potential is particularly relevant in tissues with low NQO1 activity and should be considered when evaluating idebenone use outside of established complex I deficiency contexts.
Immune System Considerations
Idebenone has not been administered (to the knowledge of protocol investigators) to patients with presumed immune-mediated disorders, and therefore the effect of idebenone on dysregulated immune responses in humans is currently unknown and difficult to predict. Because several functions of the immune system are dependent on the formation of ROS, a potent antioxidant may theoretically inhibit these functions.
Drug Interactions
No well-documented pharmacokinetic drug interactions for idebenone were identified in the reviewed clinical trial literature. Given that more than 99% of the circulating drug is bound to plasma proteins, interactions with other highly protein-bound drugs are theoretically plausible but have not been characterized in peer-reviewed studies. The compound's dependence on NQO1 for bioactivation means that drugs or conditions that modulate Nrf2/NQO1 expression could theoretically alter idebenone's efficacy or toxicity profile.
Long-Term Use and High-Dose Safety
As idebenone is clinically available, it undoubtedly has good safety profiles in humans at doses above 2,250 mg/day. No new issues of safety or tolerability have emerged in the course of Phase II and III clinical studies with idebenone in Friedreich's Ataxia, Duchenne Muscular Dystrophy, and Leber's Hereditary Optic Neuropathy.
9. Regulatory Status Summary
- European Union: Approved by the EMA in 2015 as Raxone® for treating LHON at 900 mg/day.
- United States: The FDA has accepted for review a New Drug Application for idebenone for LHON. It is not currently FDA-approved for any indication.
- Japan: Marketed from 1986 to 1998 for cognitive difficulties following stroke; withdrawn after post-marketing failure to demonstrate efficacy. Remains registered in some other countries.
- Orphan drug designation: Because the number of patients with LHON is low, the disease is considered "rare," and Raxone was designated an "orphan medicine" on 15 February 2007.
References
Go back